Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 09, 2025, titled "CuraTeQ Biologics completes a successful Phase 1 Pharmacokinetics study of Denosumab BP16, a proposed biosimilar to Prolia? and Xgeva?".
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma's subsidiary CuraTeQ Biologics has successfully completed a Phase 1 Pharmacokinetics study for Denosumab BP16, a proposed biosimilar to Amgen's blockbuster drugs Prolia (osteoporosis) and Xgeva (bone metastases). Prolia and Xgeva together generated multi-billion dollar global revenues for Amgen, making them attractive biosimilar targets. This is an early-stage clinical milestone confirming that the biosimilar behaves similarly to the original drug in the human body. The result moves the product one step closer to further clinical trials and eventually regulatory approval, but no timeline for market launch has been announced.
Positive for Aurobindo's long-term biologics pipeline and credibility in the high-value biosimilars space, but no immediate revenue impact as this is still an early-stage development update with years of trials and approvals likely ahead.